Brahmoside (Triterpenoid Saponin · CNS Anxiolytic · Brahmi Minor Active)

Compound	Brahmoside
Chemical class	Terpenoid — Triterpenoid Saponin (Pseudojujubogenin aglycone glycoside)
CAS	17747-72-7
Primary source	Bacopa monnieri (Brahmi) and Centella asiatica (Gotu Kola) — minor constituent
Key applications	CNS sedative/anxiolytic, cognitive modulation, Bacopa minor active
Claim strength	Moderate
Typical form	Bacopa monnieri extract (brahmoside as minor bacoside fraction); Centella asiatica co-constituent
Buy from Herbuno	Organic Brahmi (Bacopa monnieri) Leaf Powder → Brahmi Liquid Extract (Water Soluble) - Bacopa Monnieri →

Name origin: From Brahmi — the Sanskrit name for Bacopa monnieri, reflecting its primary botanical source. Brahmoside is a pseudojujubogenin aglycone glycoside — structurally distinct from the jujubogenin-based bacosides A and B, representing a distinct triterpenoid saponin class within the Bacopa phytochemical profile. Traditional use: Brahmoside has not been individually targeted in traditional medicine — it was identified as a constituent of Bacopa during systematic phytochemical characterisation. Its pharmacological properties have been attributed retrospectively to Brahmi’s traditional CNS applications. Research trajectory: Brahmoside has been specifically studied for CNS depressant (sedative), anxiolytic, and cardiovascular effects in animal models. It appears to contribute to Bacopa’s overall anxiolytic activity alongside the serotonergic effects of bacosides A and B. It is considered a minor but pharmacologically active constituent of the total bacoside complex. Commercial source: Available as a constituent of Brahmi (Bacopa monnieri) extract. See sourcing options below.

---

Evidence for Brahmoside Applications

CNS depressant and anxiolytic: Brahmoside produces dose-dependent CNS depressant effects in animal models — prolonging pentobarbitone sleeping time, reducing spontaneous motor activity, and producing anxiolytic effects in maze tests. The mechanism involves modulation of GABA-A receptors and possibly opioid receptor partial agonism. Contributes to Bacopa’s overall sedative-anxiolytic profile distinct from the cognitive-enhancing mechanisms of bacosides A3 and bacopaside II. Claim strength: Moderate (animal data; human attribution limited to Bacopa extract studies).

Cardiovascular modulation: Brahmoside and brahmosine (the two pseudojujubogenin saponins in Bacopa) reduce heart rate and blood pressure in animal models via direct cardiac effects and possibly calcium channel modulation. May contribute to the cardiovascular safety profile of Bacopa at higher doses. Claim strength: Emerging.

Anti-inflammatory: Brahmoside demonstrates NF-κB inhibitory activity in cell models. The pseudojujubogenin scaffold provides a distinct anti-inflammatory mechanism profile from the jujubogenin-based bacosides. Claim strength: Emerging.

---

Dosage & Formulator Specification

Brahmoside is not commercially formulated as a standalone ingredient. It is a constituent of the total bacoside fraction in Bacopa monnieri extract. Commercial Bacopa extracts standardised to total bacosides (20–55%) co-deliver brahmoside and brahmosine as a defined minor fraction of the saponin complex. For formulations specifically targeting brahmoside’s anxiolytic contribution, the standard Bacopa extract at clinical doses (300–450 mg/day, 55% total bacosides) is the appropriate delivery vehicle. No isolated brahmoside is commercially available at supplement scale.

---

Frequently Asked Questions — Brahmoside

How does brahmoside differ from bacoside A?
Brahmoside is a pseudojujubogenin aglycone glycoside; bacoside A comprises jujubogenin aglycone glycosides. These are structurally distinct triterpene saponin classes with different aglycone scaffolds. The distinct structure gives brahmoside a different pharmacological profile — more CNS depressant/anxiolytic versus bacoside A’s AChE inhibitory/procognitive mechanisms. Together they contribute to Bacopa’s combined cognitive-anxiolytic effect profile.

Is brahmoside responsible for Bacopa’s sedative effects at high doses?
Brahmoside’s CNS depressant activity in animal models is consistent with the sedative side effects reported at higher Bacopa doses in some human RCTs. The sedative effect is dose-dependent and generally considered a side effect rather than a desired outcome at clinical doses — it can impair alertness when taken in the morning at high doses. This is why some protocols recommend evening dosing or starting at lower doses.

Does brahmoside occur in Centella asiatica (Gotu Kola) as well?
Brahmoside has been reported as a minor constituent in some Centella asiatica preparations, though it is not the primary or best-characterised saponin in Gotu Kola (which is standardised to asiaticoside and madecassoside). Any brahmoside present in Centella is at much lower concentrations than in Bacopa. For brahmoside activity, Bacopa monnieri extract is the appropriate botanical source.

Is brahmoside the same as brahmosine?
No. Brahmoside and brahmosine are closely related pseudojujubogenin glycoside saponins that co-occur in Bacopa monnieri, named as a pair reflecting their Brahmi origin. They share the pseudojujubogenin aglycone but differ in their sugar chain composition and linkages. Both are present as minor constituents of the total bacoside fraction alongside the more abundant jujubogenin-based bacosides A and B.

Related compounds: Bacoside A, Bacosides, Asiaticoside, Ginsenosides

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery